Invivoscribe - Improving Lives with Precision Diagnostics®

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics^®

Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient.

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

LEARN MORE ⟶

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

LEARN MORE ⟶

Invivoscribe-Parnterships-Category-Image-003

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

LEARN MORE ⟶

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics^®

Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient.

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

LEARN MORE ⟶

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

LEARN MORE ⟶

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

LEARN MORE ⟶

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles and Press Releases

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

admin2020-05-19T16:22:45+00:00May 19th, 2020|Press Releases|

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-15T18:55:49+00:00May 15th, 2020|Events, Upcoming Events|

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

admin2020-05-12T17:03:17+00:00May 12th, 2020|Press Releases|

Invivoscribe Launches COVID-19 Diagnostic Testing with Option to Participate in SARS-CoV-2 Antibody and Vaccine Program

admin2020-04-28T02:03:31+00:00April 28th, 2020|Press Releases|

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

admin2019-12-19T21:12:13+00:00December 5th, 2019|Press Releases|

ALL RELATED ARTICLES ⟶

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles
and Press Releases

Invivoscribe Announces FDA Approval for Distribution of the LeukoStrat CDx FLT3 Mutation Assay as an IVD Kit in the United States

admin2020-05-19T16:22:45+00:00May 19th, 2020|Press Releases|

Invivoscribe to Participate in Virtual ASCO 2020

admin2020-05-15T18:55:49+00:00May 15th, 2020|Events, Upcoming Events|

Invivoscribe Submits LeukoStrat® CDx FLT3 Mutation Assay to NMPA in China and Expands Company, Adding Laboratory in Shanghai to Provide Comprehensive Support for Partners.

admin2020-05-12T17:03:17+00:00May 12th, 2020|Press Releases|

Invivoscribe Launches COVID-19 Diagnostic Testing with Option to Participate in SARS-CoV-2 Antibody and Vaccine Program

admin2020-04-28T02:03:31+00:00April 28th, 2020|Press Releases|

The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay

admin2019-12-19T21:12:13+00:00December 5th, 2019|Press Releases|

ALL RELATED ARTICLES ⟶

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS COVID-19 TESTING Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

Browse our comprehensive menu of product & testing services.

A proven strategy to acceleratedrug approvals

Design Controls, Bioinformatics Software, Identify & Track, Custom Development, and Complementary MRD Assays

cGMP Compliant, CE-marked IVDs & CDx Manufacturing, Assay Development, and Controls & Reagents

Clinical Lab Experience, Internationally Standardized, Comprehensive Panels, Complementary MRD Assays, and Worldwide Enrollment

Accredited & Proven, Registered Medical Device Establishment, Multiple CDx Approvals, CE-marked IVDs, and Marketing Authorization Holder (MAH)

We take pride in expanding the science that bridges personalized medicine with quality healthcare.

Personalized Molecular Medicine® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019 Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018 A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018 Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics®

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

INDUSTRY PIONEERS

Improving Lives with Precision Diagnostics®

Invivoscribe is an industry pioneer with over 20 years of experience developing and manufacturing diagnostic products and reagents for leukemias and lymphomas. All of our diagnostic tests generate meaningful results allowing healthcare providers to confirm or modify treatment for each patient.

PRODUCTS

Best in class assays and reagents

Invivoscribe provides a full range of standardized CE-marked in vitro diagnostic cGMP products for hematology-oncology, as well as RUO assays, analyte specific reagents (ASRs), and DNA & RNA controls.

CLINICAL LAB SERVICES

LabPMM offers clinical services with global reach

The Laboratory for Personalized Molecular Medicine® (LabPMM®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

PARTNERSHIPS

CDx Turn-Key Collaboration

Invivoscribe provides a proven strategy to accelerate drug approvals, offering Product Development, Manufacturing, Clinical Lab Services and Global Regulatory Expertise.

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles and Press Releases

CONNECT

Invivoscribe Newsroom

The Latest Publications, News, Articles and Press Releases

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally standardized testing of novel and proprietary biomarkers that are critically important for patient care.

CORONAVIRUS
COVID-19 TESTING

Performed with real-time reverse transcription polymerase chain reaction (RT-PCR) to detect nucleic acid from SARS-CoV-2.

A proven strategy to accelerate
drug approvals

Personalized Molecular Medicine^® is use of genomics and patient specific information to identify optimal treatment for each patient.

March 21st, 2019
Establishment of Immunoglobulin Heavy (IGH) Chain Clonality Testing by Next-Generation Sequencing for Routine Characterization of B-Cell and Plasma Cell Neoplasms

August 25th, 2018
A next-generation sequencing–based assay for minimal residual disease assessment in AML patients with FLT3-ITD mutations

August 22nd, 2018
Simple deep sequencing-based post-remission MRD surveillance predicts clinical relapse in B-ALL

Improving Lives with Precision Diagnostics^®

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

Improving Lives with Precision Diagnostics^®

The Laboratory for Personalized Molecular Medicine^® (LabPMM^®) at Invivoscribe offer internationally harmonized testing of novel and proprietary biomarkers that are critically important for patient care.

The Latest Publications, News, Articles
and Press Releases